Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRXFree Report) by 257.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,450 shares of the biopharmaceutical company’s stock after buying an additional 32,009 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Royalty Pharma were worth $1,249,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in RPRX. Allworth Financial LP boosted its stake in Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 731 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 802 shares during the last quarter. Lindbrook Capital LLC grew its stake in Royalty Pharma by 485.2% in the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,999 shares in the last quarter. Parallel Advisors LLC increased its holdings in Royalty Pharma by 62.7% in the fourth quarter. Parallel Advisors LLC now owns 2,882 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 1,111 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Royalty Pharma by 295.8% during the fourth quarter. Quadrant Capital Group LLC now owns 3,487 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 2,606 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.3 %

Shares of NASDAQ:RPRX opened at $27.39 on Tuesday. Royalty Pharma plc has a fifty-two week low of $25.92 and a fifty-two week high of $33.86. The company has a quick ratio of 12.52, a current ratio of 12.52 and a debt-to-equity ratio of 0.62. The company has a market cap of $16.36 billion, a PE ratio of 20.44, a P/E/G ratio of 3.58 and a beta of 0.47. The company’s 50-day moving average price is $27.89 and its 200 day moving average price is $28.61.

Royalty Pharma (NASDAQ:RPRXGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The business had revenue of $568.00 million during the quarter, compared to the consensus estimate of $671.45 million. During the same period in the previous year, the firm posted $1.60 earnings per share. Sell-side analysts anticipate that Royalty Pharma plc will post 4.03 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 annualized dividend and a dividend yield of 3.07%. Royalty Pharma’s payout ratio is 62.69%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on RPRX. UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price for the company. in a research report on Monday, June 3rd. The Goldman Sachs Group lowered their target price on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Bank of America reduced their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, April 12th. StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, JPMorgan Chase & Co. cut their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a report on Tuesday, February 20th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Read Our Latest Stock Analysis on Royalty Pharma

About Royalty Pharma

(Free Report)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Stories

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.